印度制药公司Indoco Remedies获得美国FDA对通用洛菲克西丁片的最终批准,授予180天的CGT专用权. Indian pharmaceutical company Indoco Remedies receives final USFDA approval for generic Lofexidine tablets, granting 180-day CGT exclusivity.
印度制药公司Indoco Remedies获得美国FDA对其用于阿片类药物停用治疗的仿制洛菲克辛片的最终批准,并授予其180天的竞争性仿制疗法 (CGT) 独家权. Indian pharmaceutical company Indoco Remedies received final USFDA approval for its generic Lofexidine tablets, used in opioid discontinuation treatment, granting them 180 days of competitive generic therapy (CGT) exclusivity. 作为首个已获批准的仿制药,Indoco Remedies计划立即在美国市场推出该产品,目标市场为1559万美元,增长潜力为38%. As the first approved generic, Indoco Remedies plans to launch the product immediately in the US market, targeting a $15.59m market with 38% growth potential. 药物估计销售量 使公司得以加强其在美国市场的地位 The drug's estimated sales enable the company to strengthen its position in the US market.